Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalacne of Neurological Disorders
4.2.2 Rising Number of Smokers
4.3 Market Restraints
4.3.1 Heavy costs associated with diagnosis
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Diagnostic Type
5.1.1 Imaging Test
5.1.1.1 MRI
5.1.1.2 CT Scan
5.1.1.3 Other
5.1.2 Lumbar Puncture
5.1.3 Biopsy
5.1.4 Molecular Testing
5.1.5 Others
5.2 By Tumor Type
5.2.1 Metastatic
5.2.2 Meningioma
5.2.3 Glioblastoma
5.2.4 Astrocytoma
5.2.5 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostics Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Koninklijke Philips N.V.
6.1.3 Siemens Healthcare GmbH
6.1.4 Fujifilm Corporation
6.1.5 Hitachi, Ltd.
6.1.6 Hologic, Inc.
6.1.7 NantOmics
6.1.8 Thermo Fisher Scientific


7 MARKET OPPORTUNITIES AND FUTURE TRENDS